<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32719333</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model.</ArticleTitle><Pagination><StartPage>3753</StartPage><MedlinePgn>3753</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3753</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-17514-9</ELocationID><Abstract><AbstractText>Reactive astrocytes have been implicated in the pathogenesis of neurodegenerative diseases, including a non-cell autonomous effect on motor neuron survival in ALS. We previously defined a mechanism by which microglia release three factors, IL-1&#x3b1;, TNF&#x3b1;, and C1q, to induce neurotoxic astrocytes. Here we report that knocking out these three factors markedly extends survival in the SOD1<sup>G93A</sup> ALS mouse model, providing evidence for gliosis as a potential ALS therapeutic target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guttenplan</LastName><ForeName>Kevin A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-4242-4349</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, 94305, CA, USA. kguttenp@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, School of Medicine, Stanford University, Stanford, 94305, CA, USA. kguttenp@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigel</LastName><ForeName>Maya K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, 94305, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Drew I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, NYU School of Medicine, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couthouis</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2378-4595</Identifier><AffiliationInfo><Affiliation>Department of Genetics, School of Medicine, Stanford University, Stanford, 94305, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-0840-1437</Identifier><AffiliationInfo><Affiliation>Neuroscience Institute, NYU School of Medicine, New York, NY, 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Physiology, NYU School of Medicine, New York, NY, 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, NYU School of Medicine, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0001-8603-1526</Identifier><AffiliationInfo><Affiliation>Department of Genetics, School of Medicine, Stanford University, Stanford, 94305, CA, USA. agitler@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, 94305, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS069375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD020141</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053582">Interleukin-1alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053582" MajorTopicYN="N">Interleukin-1alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>A.D.G. has served as a consultant for Aquinnah Pharmaceuticals, Prevail Therapeutics, and Third Rock Ventures, and is a scientific founder of Maze Therapeutics. S.A.L. is an academic founder of AstronauTx Ltd. B.A.B. is a co-founder of Annexon Biosciences Inc., a company working to make new drugs for treatment of neurological diseases. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32719333</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pii">10.1038/s41467-020-17514-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgio F, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non&#x2013;cell autonomous effect of glia on motor neurons in an embryonic stem cell&#x2013;based ALS model. Nat. Neurosci. 2007;10:608&#x2013;614. doi: 10.1038/nn1885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1885</ArticleId><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc. Natl Acad. Sci. USA. 2016;113:E6496&#x2013;E6505. doi: 10.1073/pnas.1607496113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1607496113</ArticleId><ArticleId IdType="pmc">PMC5081600</ArticleId><ArticleId IdType="pubmed">27688759</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. 2006;103:16021&#x2013;16026. doi: 10.1073/pnas.0607423103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607423103</ArticleId><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117. doi: 10.1126/science.1086071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086071</ArticleId><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Gutmann DH, Roos RP. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 2011;20:286&#x2013;293. doi: 10.1093/hmg/ddq463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq463</ArticleId><ArticleId IdType="pubmed">20962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Sharma K, Grisotti G, Roos RP. The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol. Dis. 2009;35:234&#x2013;240. doi: 10.1016/j.nbd.2009.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.05.002</ArticleId><ArticleId IdType="pmc">PMC2706919</ArticleId><ArticleId IdType="pubmed">19442735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc. Natl Acad. Sci. 2008;105:7594&#x2013;7599. doi: 10.1073/pnas.0802556105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802556105</ArticleId><ArticleId IdType="pmc">PMC2396671</ArticleId><ArticleId IdType="pubmed">18492803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013;16:571&#x2013;579. doi: 10.1038/nn.3357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3357</ArticleId><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Investig. 2018;128:3558&#x2013;3567. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Investig. 2006;116:2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G, Dequen F, Soucy G, Julien J-P. Absence of tumor necrosis factor- does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J. Neurosci. 2006;26:11397&#x2013;11402. doi: 10.1523/JNEUROSCI.0602-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0602-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674545</ArticleId><ArticleId IdType="pubmed">17079668</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitpain N, et al. Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis? Fundam Clin. Pharm. 2019;33:689&#x2013;694. doi: 10.1111/fcp.12480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12480</ArticleId><ArticleId IdType="pubmed">31058354</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Ripley B, Serada S, Naka T, Fujimoto M. Interleukin-6 deficiency does not affect motor neuron disease caused by superoxide dismutase 1 mutation. PLoS ONE. 2016;11:e0153399. doi: 10.1371/journal.pone.0153399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0153399</ArticleId><ArticleId IdType="pmc">PMC4829212</ArticleId><ArticleId IdType="pubmed">27070121</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Julien J-P, Rivest S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann. Neurol. 2001;50:630&#x2013;639. doi: 10.1002/ana.1256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1256</ArticleId><ArticleId IdType="pubmed">11706969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobsiger CS, et al. C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc. Natl Acad. Sci. 2013;110:E4385&#x2013;E4392. doi: 10.1073/pnas.1318309110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318309110</ArticleId><ArticleId IdType="pmc">PMC3831990</ArticleId><ArticleId IdType="pubmed">24170856</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi F, et al. Reactive astrocytes secrete lcn2 to promote neuron death. Proc. Natl Acad. Sci. USA. 2013;110:4069&#x2013;4074. doi: 10.1073/pnas.1218497110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218497110</ArticleId><ArticleId IdType="pmc">PMC3593910</ArticleId><ArticleId IdType="pubmed">23431168</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo LC, et al. Development of a method for the purification and culture of rodent astrocytes. Neuron. 2011;71:799&#x2013;811. doi: 10.1016/j.neuron.2011.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.07.022</ArticleId><ArticleId IdType="pmc">PMC3172573</ArticleId><ArticleId IdType="pubmed">21903074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, et al. New tools for studying microglia in the mouse and human CNS. Proc. Natl Acad. Sci. 2016;113:E1738&#x2013;E1746. doi: 10.1073/pnas.1525528113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525528113</ArticleId><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, et al. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron. 2017;94:759&#x2013;773. doi: 10.1016/j.neuron.2017.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Liddelow SA. Astrocytes and microglia: models and tools. J. Exp. Med. 2018;216:71&#x2013;83. doi: 10.1084/jem.20180200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180200</ArticleId><ArticleId IdType="pmc">PMC6314517</ArticleId><ArticleId IdType="pubmed">30541903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proc. Natl Acad. Sci. 2015;112:E6993&#x2013;E7002. doi: 10.1073/pnas.1520639112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1520639112</ArticleId><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, et al. Normal aging induces A1-like astrocyte reactivity. Proc. Natl Acad. Sci. 2018;115:201800165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert MM, Erikson GA, Shokhirev MN, Allen NJ. The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Rep. 2018;22:269&#x2013;285. doi: 10.1016/j.celrep.2017.12.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.039</ArticleId><ArticleId IdType="pmc">PMC5783200</ArticleId><ArticleId IdType="pubmed">29298427</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AU, et al. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat. Neurosci. 2019;22:1635&#x2013;1648. doi: 10.1038/s41593-019-0486-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0486-0</ArticleId><ArticleId IdType="pmc">PMC6764589</ArticleId><ArticleId IdType="pubmed">31551592</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523. doi: 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun SP, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson&#x2019;s disease. Nat. Med. 2018;24:931&#x2013;938. doi: 10.1038/s41591-018-0051-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0051-5</ArticleId><ArticleId IdType="pmc">PMC6039259</ArticleId><ArticleId IdType="pubmed">29892066</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, et al. Neurotoxic reactive astrocytes drive neuronal death after retinal injury. Cell Rep. 2020;31:107776. doi: 10.1016/j.celrep.2020.107776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107776</ArticleId><ArticleId IdType="pubmed">32579912</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinform. Oxf. Engl. 2012;29:15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>